•  
  •  
  •  
  •  

2026-08-06 23:46:57

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Deepening Our Presence in Punjab - Strengthening the Tricity Cluster
  • Mini Diamonds India Reports Strong Q1 FY27 Performance: Consolidated Net Profit Up 49.8% YoY to ₹2.67 Crore; Revenue Nearly Doubles to ₹196.53 Crore
  • Kinetic Engineering Reports Q1 FY27 Results: Net Loss at ₹12.96 Crore Amid Higher Material Costs and Inventory Movements
  • Blue Jet Healthcare Reports Q1 FY27 Results: Net Profit Reaches ₹78.26 Crore; Revenue Up 24.9% QoQ
  • One Mobikwik Systems Turns Profitable in Q1 FY27: Reports Net Profit of ₹7.62 Crore; EBITDA Reaches ₹15.78 Crore

Keywords Selected:  INE935A01035

Stock Report

  • Glenmark Pharmaceuticals Announces Q1 FY27 Results
  • Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials
  • Glenmark Receives U.S. FDA Approval to Expand the Use of RYALTRIS® Nasal Spray for Children Aged 6 to Less Than 12 Years
  • Glenmark Pharmaceuticals Inc., USA launches Olanzapine for Injection, 10 mg/vial, Single-Dose Vial
  • Glenmark Advances Multi-Country Phase 3 Clinical Trial of Trastuzumab rezetecan in Platinum-Resistant Ovarian Cancer
  • US FDA inspection at Glenmark Pharmaceuticals Ltd's manufacturing facility in Goa, India
  • Glenmark Pharmaceuticals Inc., USA launches Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial
  • Glenmark Launches Winlevi® 10 mg/g cream in Key European Markets for the Treatment of Acne Vulgaris
  • Glenmark Pharmaceuticals Inc., USA launches Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials
  • Glenmark Pharmaceuticals Receives U.S. FDA Approval for Progesterone Vaginal Inserts, 100 mg
  • Glenmark Pharmaceuticals announces Strategic Shift to Direct Commercialization and Distribution of RYALTRIS® in the U.S.
  • Glenmark Pharmaceuticals Launches GLIPIQ® (Semaglutide) In India
  • Glenmark Pharmaceuticals Inc., USA launches Authorized Generic to Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg, and 100 mg
  • Glenmark Therapeutics Inc., USA launches Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC)
  • Glenmark Pharmaceuticals Inc., USA to launch Potassium Phosphates Injections
  • Glenmark Specialty SA Receives U.S. FDA Approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, with 180-Day Competitive Generic Therapy Exclusivity
  • Glenmark Pharmaceuticals Inc., USA to launch Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials
  • Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial
  • Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma
  • Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma
  • Glenmark Pharmaceuticals Inc., USA to launch Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial
  • Glenmark Pharmaceuticals Ltd update on USFDA PAI at Chhatrapati Sambhajinagar Facility
  • Glenmark Pharmaceuticals Receives Establishment Inspection Report (EIR) from U.S. FDA for its Monroe facility
  • Glenmark Pharmaceuticals announces Launch of Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, World's First Nebulized Triple Therapy for COPD

Latest Post

  • Deepening Our Presence in Punjab - Strengthening the Tricity Cluster
  • Mini Diamonds India Reports Strong Q1 FY27 Performance: Consolidated Net Profit Up 49.8% YoY to ₹2.67 Crore; Revenue Nearly Doubles to ₹196.53 Crore
  • Kinetic Engineering Reports Q1 FY27 Results: Net Loss at ₹12.96 Crore Amid Higher Material Costs and Inventory Movements
  • Blue Jet Healthcare Reports Q1 FY27 Results: Net Profit Reaches ₹78.26 Crore; Revenue Up 24.9% QoQ
  • One Mobikwik Systems Turns Profitable in Q1 FY27: Reports Net Profit of ₹7.62 Crore; EBITDA Reaches ₹15.78 Crore


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025